Benfotiamine
Synthetic S-acyl thiamine derivative used as a vitamin B1 precursor. Intestinal dephosphorylation produces a more membrane-permeable S-benzoylthiamine intermediate, which is absorbed and converted to thiamine and its phosphorylated cofactor forms. Human trials have studied diabetic neuropathy and early Alzheimer disease, but efficacy is not established: a 2026 year-long neuropathy trial found no significant benefit across its primary morphometric, neurophysiological, or clinical outcomes.
Projected serum levels — 300 mg, once daily
Maintenance schedule: 300 mg once daily (oral).
Modeled steady state after ~1 days: peak ≈ 20.7 mg, trough ≈ 0.000 mg body load. Population-based estimate over 15 days for a 300 mg dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.
Key facts
- Category
- Vitamin
- Route modeled
- Oral
- Model confidence
- inferred
- Half-life
- 29 h
- Common dose
- 300 mg
- Suggested maximum
- 600 mg/day
- Reference dose range
- 150–600 mg (single dose)
- Suggested cadence
- once daily
- Validated against
- 300 mg oral — Cmax 0.62 mg/L at 1.5 h
Research behind this entry
-
Pharmacokinetic study of benfotiamine and the bioavailability assessment compared to thiamine hydrochloride
Human single- and multiple-dose PK study measuring thiamine, TMP, and TDP after oral benfotiamine. Relative to oral thiamine hydrochloride, plasma thiamine exposure was about 11.5-fold higher and erythrocyte TDP…
-
Safety, tolerability and pharmacokinetics of single and multiple ascending doses of benfotiamine in healthy subjects
Two randomized phase I studies evaluated single doses from 150-1200 mg and repeated doses from 150-600 mg in healthy adults. Generated thiamine peaked at 1-2 hours, while TMP and TDP peaked later. Exposure was analyte-…
-
Benfotiamine and cognitive decline in Alzheimer's disease
In a 12-month phase IIa placebo-controlled trial, 34 participants received benfotiamine and 36 received placebo. The primary ADAS-Cog comparison did not reach statistical significance (p=0.125). CDR worsening and an…
-
Effects of benfotiamine treatment over 12 months in type 2 diabetes patients with symptomatic polyneuropathy
This randomized double-blind phase II trial compared benfotiamine 300 mg twice daily with placebo for 12 months. Treatment was well tolerated but produced no significant benefit across the studied morphometric,…
4 published studies referenced in the app, each with a plain-language summary.